- NEWS FEATURE
How a controversial US drug policy could be harming cancer patients worldwide
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 620, 264-267 (2023)
doi: https://doi.org/10.1038/d41586-023-02492-x
References
Miles, D. et al. Ann. Oncol. 32, 994–1004 (2021).
Parikh, R. B. et al. JAMA Oncol. 9, 567–569 (2023).
Belin, L., Tan, A., De Rycke, Y & Dechartres, A. Br. J. Cancer 122, 1707–1714 (2020).
Mooghali, M. et al. J. Clin. Oncol. 41, 1590 (2023).
Akhade, A., Sirohi, B. & Gyawali, B. Lancet Oncol. 23, 201–203 (2022).